Screening for cardiovascular disease with cholesterol

Clinica Chimica Acta

Volumn 315, Issue 1-2, 2002, Pages 49-60

  Sullivan, David R ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Cholesterol; Prevention; Screening

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SATURATED FATTY ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST BENEFIT ANALYSIS; DIET; ENVIRONMENTAL FACTOR; EPIDEMIC; EXERCISE; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MORBIDITY; MORTALITY; PATIENT ATTITUDE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; EXERCISE; FOOD HABITS; HUMANS; MASS SCREENING; PRIMARY PREVENTION; RISK FACTORS;

EID: 0036133032     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00720-3     Document Type: Review

References (59)

1. Cholesterol screening is not worth while
2. The diet and 15-year death rate in the seven countries study
3. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
4. The Australian Burden of Disease Study: Measuring the loss of health from diseases, injuries and risk factors
5. Emerging epidemic of cardiovascular disease in developing countries
6. Serum cholesterol and coronary heart disease in population with low cholesterol concentrations
7. Task force 3. Spectrum of risk factors for coronary heart disease
8. Prediction of coronary heart disease using risk factor categories
9. Cardiovascular monitoring of a city over 30 years
10. The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial
11. Cholesterol reduction yields clinical benefit: Impact of statin trials
12. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease?
13. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein
14. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol
15. Estimating and minimizing effects of biological sources of variation by relative range when measuring mean of serum lipids and lipoproteins
16. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in cholesterol and recurrent events (CARE) trial
17. Laboratory standardization of a large clinical trial: The DAIS experience
18. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
19. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolemia
20. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial
21. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
22. The cost effectiveness of lipid lowering in Swedish primary health care
23. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications
24. Apolipoproteins and ischemic heart disease: Implications for screening
25. The tangled web of coronary risk factors
26. Diabetes mellitus: Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality
27. Nutrition and cardiovascular disease: An Asia Pacific perspective
28. Common and rare ABC-AI variants affecting plasma HDL cholesterol
29. Prevalence of risk factors in men with premature coronary artery disease
30. Efficacy of lipid profiles in prediction of coronary disease
31. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
32. Epidemiologic aspects of lipid abnormalities
33. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies
34. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
35. Nontraditional cardiovascular risk factors
36. Recent data are not in conflict with homocysteine as a cardiovascular risk factor
37. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual?
38. High risk strategies for atherosclerosis
39. The pathophysiology of acute coronary syndromes
40. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries
41. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening
42. An evaluation of the Reflotron for the determination of plasma cholesterol in capillary blood. Effect of operator variability
43. Is knowing your cholesterol number harmful?
44. The target plot: A new way of displaying the performance of a screening test
45. Prevalence-value-accuracy plots: A new method for comparing diagnostic tests based on misclassification costs
46. Task Force 6: Cost effectiveness of assessment and management of risk factors
47. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
48. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics
49. Five-hundred life-saving interventions and their cost-effectiveness
50. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: Cross sectional study of cardiovascular disease and risk factors
51. The long-term intervention with pravastatin (LIPID) Study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
52. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
53. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
54. Prevention of coronary heart disease with pravastatin
55. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
56. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia
57. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
58. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
59. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol